Chiesi to Acquire Amryt Pharma for ~$1.48B
Shots:
- Amryt shareholders will receive $14.50 per ADS up front & CVR of ~$2.50 per ADS (in total about $225M) based on the achievement of milestones related to Amryt's product Filsuvez representing a total transaction value of (~$1.25B in upfront consideration & $0.225B in CVR) at a premium of 107% to Amryt ADS’ closing price on Jan 2023. The transaction is expected to close at the end of H1’23
- The acquisition will accelerate Chiesi’s rare disease medicine portfolio & expertise that helps to provide therapies to patients with rare diseases. The therapy is already approved in the EU for epidemolysis bullosa
- The Chiesi’s goal is to improve people’s QoL while Amryt focuses to bring innovative products to new markets
Ref: Globenewswire | Image: Amryt Pharma
Related News:- Chiesi Farmaceutici Licenses Tum Bio's NCE401 for $74M
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
